Skip to main content
. 2021 Jul 31;7:199. doi: 10.1038/s41420-021-00583-0

Fig. 5. MEK inhibition by selumetinib reduces RASSF9-induced NSCLC cell viability and proliferation.

Fig. 5

a Selumetinib reduces RASSF9-induced upregulation of cell viability. A549, H1299, and H1650 cells were transfected with the plasmid expressing Rassf9. Twelve hours post-transfection, cells were treated with 10 μM of selumetinib for additional 24 h and then subjected for cell viability assay by the method of MTT. b Selumetinib decreases RASSF9-induced EdU incorporation. Cell treatments were described in (a). Scale bar = 500 μm. c Quantitative analysis for EdU incorporation. Data are presented as means ± SD (error bars). *P < 0.05, **P < 0.01, and ***P < 0.001. One-way ANOVA test.